Obesity
Not yet recruitingKAI-9531 in Adults With Obesity or Overweight and Diabetes
KAI-9531 in Adults With Obesity or Overweight and Diabetes
Germany- Participants:18–64 years · 65+ years
- Substances:HRS 9531
- Sponsor:Kailera Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany1 691 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)KAI-9531 in Adults With Obesity or Overweight and Diabetes
GermanyA study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.
GermanyA study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis
GermanyA study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis
GermanyA study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease
GermanyStudy of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)
GermanyEfficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors
GermanyStudy on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older
GermanyStudy of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma
GermanyStudy on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis
GermanyStudy on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults
GermanyStudy on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen
GermanyThe busiest research cities in the country
What the registry says about research in the country
Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.
Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.
Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.
Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.
Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.
Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.
Tell us about your condition – we search every trial in Europe and connect you with the right site.